RNA-based Therapeutics in Cardiology: Dawn of a New Era? |Biomedgrid

The COVID-19 pandemic had the inadvertent effect of bringing RNA-based therapeutics on to center stage, as both the Pfizer-BioNTech and Moderna COVID vaccines (BNT162b2 and mRNA-1273, respectively) were made of mRNA species that were chemically modified and encapsulated in lipid-nanoparticles to elicit a robust protective immune response against SARS-Co-V-2 virus. With this newfound spotlight, RNA-based drugs may finally get a much-needed breath of new life, as the previously touted therapeutic class with much potential has struggled for years to materialize into practical treatment options in clinical medicine.